| abstract |
A combination of compounds for use in the therapeutic or prophylactic treatment of an infection by an Immunodeficiency Virus wherein the compounds are administered sequentially to a mammalian host, to elicit a specific cellular protective immune response against said infection, which comprises at least : (i) lentiviral vector particles, pseudotyped with a first glycosylated (G) protein determined from a Vesicular Stomatitis Virus (VSV); (ii) lentiviral vector particles, pseudotyped with a second determined VSV G protein different from said first determined VSV G protein; wherein said lentiviral vector particle of (i) and (ii) comprises in its genome a recombinant polynucleotide encoding one or more polypeptides comprising at least one antigen from a GAG antigen of said Immunodeficiency Virus and; wherein said first and second VSV G proteins are respectively VSV-G of the Indiana strain and VSV-G of the New Jersey strain, and, optionally: (iii) lentiviral vector particle, pseudotyped with a third determined VSV G protein , wherein said third VSV G protein does not sero-neutralize with said first and second VSV G proteins. |